Related Experiment Video

Updated: Jul 16, 2025

Intravital Microscopy of Tumor-associated Vasculature Using Advanced Dorsal Skinfold Window Chambers on Transgenic Fluorescent Mice
08:52

Intravital Microscopy of Tumor-associated Vasculature Using Advanced Dorsal Skinfold Window Chambers on Transgenic Fluorescent Mice

Published on: January 19, 2018

14.0K

Immunotherapies targeting tumor vasculature: challenges and opportunities

Hassan Dianat-Moghadam1,2, Reza Nedaeinia1, Mohsen Keshavarz3

  • 1Pediatric Inherited Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.

Frontiers in Immunology
|September 20, 2023
PubMed

Insights

Targeting tumor angiogenesis with antiangiogenic agents can cause resistance. Combining these therapies with immunotherapy and nanomedicine may improve cancer treatment by balancing oxygenation and tumor growth.

Area of Science:

  • Oncology
  • Vascular Biology
  • Nanomedicine

Background:

  • Angiogenesis is crucial for solid tumor growth.
  • Current antiangiogenic therapies targeting tumor vasculature or VEGF signaling face limitations like drug resistance and impaired drug delivery due to complete vascular depletion.
  • Achieving vascular normalization is key to balancing oxygenation and tumor growth inhibition.

Purpose of the Study:

  • To review approved therapies targeting tumor angiogenesis.
  • To highlight challenges and limitations of current antiangiogenic treatments.
  • To discuss the potential of vascular normalization, immunotherapy, and nanomedicine in improving cancer management.

Main Methods:

  • Literature review of approved antiangiogenic therapies.
  • Analysis of challenges associated with monotherapy and combination strategies.
  • Exploration of nanomedicine and immunotherapy roles in vascular normalization.

Main Results:

  • Antiangiogenic monotherapy has limited efficacy and can lead to resistance.
  • Combining antiangiogenic agents with immunotherapy and nanocarriers may enhance therapeutic outcomes.
  • Nanomedicine and immunotherapy can prolong the vascular normalization window.

Conclusions:

  • Vascular normalization is a critical therapeutic goal in cancer treatment.
  • Combination therapies involving antiangiogenic agents, immunotherapy, and nanomedicine offer promising strategies to overcome current treatment challenges.
  • Integrating nanomedicine and immunotherapy with vascular normalization holds theranostic potential for improved tumor management.
Keywords:
angiogenesisbiomarkerhypoxiaimmunotherapynanoparticlestumor vasculature

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.5K
Author Spotlight: Creating Human Vascularized Micro-Tumors as Models for Translational Cancer Research07:26

Author Spotlight: Creating Human Vascularized Micro-Tumors as Models for Translational Cancer Research

Published on: September 15, 2023

1.7K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
554
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
399
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.7K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
5.5K